From 0a6fdf2b31736ecf2fb19451439dc1e7c1140aeb Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 23 Apr 2026 04:22:14 +0000 Subject: [PATCH] vida: extract claims from 2026-04-23-glp1-substance-use-disorder-33-trials - Source: inbox/queue/2026-04-23-glp1-substance-use-disorder-33-trials.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...e-within-28-52-weeks-of-discontinuation.md | 7 +++++++ ...-through-mesolimbic-dopamine-modulation.md | 19 +++++++++++++++++++ ...3-glp1-substance-use-disorder-33-trials.md | 5 ++++- 3 files changed, 30 insertions(+), 1 deletion(-) create mode 100644 domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md rename inbox/{queue => archive/health}/2026-04-23-glp1-substance-use-disorder-33-trials.md (98%) diff --git a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md index e5e0c627b..b3631f869 100644 --- a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md +++ b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md @@ -32,3 +32,10 @@ WHO's conditional recommendation acknowledges 'limited long-term evidence' and ' **Source:** Frontiers in Clinical Diabetes and Healthcare 2025 review Exercise helps preserve muscle mass and sustain weight loss after GLP-1 cessation. The review states that stopping GLP-1 therapy alone leads to weight regain, but exercise provides a partial mitigation pathway. Future obesity management will likely prioritize integrated approaches (pharmacotherapy + lifestyle) rather than pharmacotherapy replacing lifestyle. + + +## Extending Evidence + +**Source:** PubMed 41696398 systematic review, 33 SUD trials + +The continuous treatment requirement extends beyond metabolic conditions to substance use disorders. The same mesolimbic dopamine circuits that mediate hedonic eating also underlie addiction, suggesting GLP-1s would require chronic administration for SUD just as they do for obesity. This creates a parallel chronic-use economic model for an entirely new therapeutic category. diff --git a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md new file mode 100644 index 000000000..220195058 --- /dev/null +++ b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md @@ -0,0 +1,19 @@ +--- +type: claim +domain: health +description: The same VTA dopamine mechanism underlying GLP-1 effects on hedonic eating extends to addiction pathways creating a potential pharmacological common denominator for reward dysregulation conditions +confidence: experimental +source: PubMed 41696398 systematic review, Qeadan et al. Addiction 2025, Harvard Gazette 2026 +created: 2026-04-23 +title: GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use +agent: vida +sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md +scope: causal +sourcer: PubMed/ClinicalTrials.gov systematic review +challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"] +related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"] +--- + +# GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use + +A systematic review of ClinicalTrials.gov identified 33 registered trials examining GLP-1 receptor agonists for substance use disorders: 15 for alcohol use disorder, 9 for nicotine/tobacco, 4 for cocaine, 4 for opioid use disorder, and 1 for methamphetamine. The mechanistic basis is shared with obesity treatment: GLP-1 receptors are expressed in the mesolimbic dopamine system (VTA, nucleus accumbens, amygdala) that underlies both hedonic eating and substance addiction. Early clinical evidence supports this mechanism: an RCT showed low-dose semaglutide reduced laboratory alcohol self-administration, drinks per drinking day, and craving in people with AUD. Real-world analysis by Qeadan et al. found that among people with pre-existing SUD, GLP-1 users showed fewer ER visits, hospitalizations, and deaths related to substance use. Animal studies demonstrate GLP-1s lower self-administration of opioids (heroin, fentanyl, oxycodone) and reduce relapse-like behavior. The breadth of the trial pipeline—with semaglutide as the most studied agent (n=15 trials)—indicates this is being taken seriously as a paradigm shift for addiction medicine. However, most OUD data remains in animal models, and human trial results are not yet published. The field is 2-3 years from definitive clinical evidence, making this experimental rather than proven. diff --git a/inbox/queue/2026-04-23-glp1-substance-use-disorder-33-trials.md b/inbox/archive/health/2026-04-23-glp1-substance-use-disorder-33-trials.md similarity index 98% rename from inbox/queue/2026-04-23-glp1-substance-use-disorder-33-trials.md rename to inbox/archive/health/2026-04-23-glp1-substance-use-disorder-33-trials.md index d21ebf643..f470d3aed 100644 --- a/inbox/queue/2026-04-23-glp1-substance-use-disorder-33-trials.md +++ b/inbox/archive/health/2026-04-23-glp1-substance-use-disorder-33-trials.md @@ -7,9 +7,12 @@ date: 2025-01-01 domain: health secondary_domains: [] format: systematic review + news synthesis -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-23 priority: high tags: [glp-1, addiction, SUD, alcohol-use-disorder, opioid-use-disorder, substance-use, clinical-trials, dopamine, reward-circuitry, semaglutide] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content